Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

7

US Approved Rx

6

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Peroxisome proliferator-activated receptor alpha

8

Taste receptor type 1 member 3

7

3-hydroxy-3-methylglutaryl-coenzyme A reductase

6

Cytochrome P450 3A4

6

HMG-CoA reductase

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

14

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1967

7

1991

6

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Hyperlipidemia

7

Hyperlipoproteinemia

7

Multiple myeloma

7

Coronary heart disease mortality and cardiovascular events

6

Homozygous and heterozygous familial hypercholesterolemia

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

14

Preventing

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck

6

Sanofi-Synthelabo

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

14

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

14

EPA CompTox

14

FDA UNII

14

PUBCHEM

14

SMS_ID

11

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

4

ALIMENTARY TRACT AND METABOLISM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

LIPID MODIFYING AGENTS

4

DRUGS USED IN DIABETES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

LIPID MODIFYING AGENTS, PLAIN

4

BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

1

LIPID MODIFYING AGENTS, COMBINATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Fibrates

3

Dipeptidyl peptidase 4 (DPP-4) inhibitors

1

HMG CoA reductase inhibitors

1

HMG CoA reductase inhibitors in combination with other lipid modifying agents

1

HMG CoA reductase inhibitors, other combinations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

11

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

TENIVASTATIN

9L6M5TH46B

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

CLOFIBRIC ACID

53PF01Q249

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1967

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Peroxisome proliferator-activated receptor alpha

Taste receptor type 1 member 3

Peroxisome proliferator-activated receptor alpha

Conditions:

Multiple myeloma

Hyperlipoproteinemia

Clofibrate is a fibric acid derivative used to lower cholesterol and triglyceride (fat-like substances) levels in the blood. This may help prevent medical problems caused by such substances clogging the blood vessels. However, this treatment was disc...

ontinued in 2002 due to adverse effects. Clofibrate is an agonist of the PPAR-α receptor in muscle, liver, and other tissues. This agonism ultimately leads to modification in gene expression resulting in increased beta-oxidation, decreased triglyceride secretion, increased HDL, and increased lipoprotein lipase activity. Clofibrate increased the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis, inhibited the synthesis, and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. In addition, clofibrate was investigated as a novel therapy agent in multiple myeloma and it shown the promising results.

CIPROFIBRATE

F8252JGO9S

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Peroxisome proliferator-activated receptor alpha

Conditions:

Ciprofibrate is an orally active phenoxyisobutyrate hypolipidemic compound. It acts by activating peroxisome proliferator activated receptor alpha. Ciprofibrate is efficacious for the correction of hyperlipidaemias.

SIMVASTATIN

AGG2FN16EV

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

TENIVASTATIN SODIUM

2L6JSY5YGL

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

TENIVASTATIN AMMONIUM

76RD797JAX

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

TENIVASTATIN CALCIUM

YNO268EI8T

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

TENIVASTATIN CALCIUM HYDRATE

QSL5L73L0O

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier organic anion transporter family member 3A1

Solute carrier organic anion transporter family member 1B1

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Cytochrome P450 3A4

HMG-CoA reductase

Conditions:

Coronary heart disease mortality and cardiovascular events

Homozygous and heterozygous familial hypercholesterolemia

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-de...

nsity lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

PYRIDOXINE CLOFIBRATE

097241263Y

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1967

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Peroxisome proliferator-activated receptor alpha

Taste receptor type 1 member 3

Peroxisome proliferator-activated receptor alpha

Conditions:

Multiple myeloma

Hyperlipoproteinemia

Clofibrate is a fibric acid derivative used to lower cholesterol and triglyceride (fat-like substances) levels in the blood. This may help prevent medical problems caused by such substances clogging the blood vessels. However, this treatment was disc...

ontinued in 2002 due to adverse effects. Clofibrate is an agonist of the PPAR-α receptor in muscle, liver, and other tissues. This agonism ultimately leads to modification in gene expression resulting in increased beta-oxidation, decreased triglyceride secretion, increased HDL, and increased lipoprotein lipase activity. Clofibrate increased the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis, inhibited the synthesis, and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. In addition, clofibrate was investigated as a novel therapy agent in multiple myeloma and it shown the promising results.

CALCIUM CLOFIBRATE

TT85QFR500

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1967

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Peroxisome proliferator-activated receptor alpha

Taste receptor type 1 member 3

Peroxisome proliferator-activated receptor alpha

Conditions:

Multiple myeloma

Hyperlipoproteinemia

Clofibrate is a fibric acid derivative used to lower cholesterol and triglyceride (fat-like substances) levels in the blood. This may help prevent medical problems caused by such substances clogging the blood vessels. However, this treatment was disc...

ontinued in 2002 due to adverse effects. Clofibrate is an agonist of the PPAR-α receptor in muscle, liver, and other tissues. This agonism ultimately leads to modification in gene expression resulting in increased beta-oxidation, decreased triglyceride secretion, increased HDL, and increased lipoprotein lipase activity. Clofibrate increased the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis, inhibited the synthesis, and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. In addition, clofibrate was investigated as a novel therapy agent in multiple myeloma and it shown the promising results.

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1